Skip to main content

Larimar Therapeutics, Inc. (LRMR)

NASDAQ: LRMR · Delayed Price · USD
12.63 1.12 (9.73%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap223.68M
Revenue (ttm)n/a
Net Income (ttm)-49.18M
Shares Out16.00M
EPS (ttm)-3.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume212,960
Open11.68
Previous Close11.51
Day's Range11.39 - 13.78
52-Week Range7.00 - 25.87
Betan/a
AnalystsStrong Buy
Price Target24.50 (+94.0%)
Est. Earnings DateNov 9, 2021

About LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.

IndustryBiotechnology
Employees28
Stock ExchangeNASDAQ
Ticker SymbolLRMR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for LRMR stock is "Strong Buy." The 12-month stock price forecast is 24.50, which is an increase of 93.98% from the latest price.

Price Target
$24.50
(93.98% upside)
Analyst Consensus: Strong Buy

News

Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...

3 days ago - GlobeNewsWire

Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...

2 weeks ago - GlobeNewsWire

Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress

BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...

1 month ago - GlobeNewsWire

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

- Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich's ataxia (FA)

1 month ago - GlobeNewsWire

Why Larimar (LRMR) Might Surprise This Earnings Season

Larimar (LRMR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Larimar (LRMR) Upgraded to Buy: Here's Why

Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021

BALA CYNWYD, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...

2 months ago - GlobeNewsWire

Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference

BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investo...

3 months ago - Newsfile Corp

Larimar Stock Craters After FDA Clinical Hold on Friedreich's Ataxia Program

The FDA has instituted a clinical hold on Larimar Therapeutics Inc's (NASDAQ: LRMR) CTI-1601 clinical program as a treatment for Friedreich's Ataxia (FA), a neurodegenerative movement disorder. The clin...

3 months ago - Benzinga

Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Fi...

BALA CYNWYD, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

3 months ago - GlobeNewsWire

Larimar Shares Trade Higher On $95M Capital Raise, CTI-1601's Priority Medicines Tag In Europe

Larimar Therapeutics Inc (NASDAQ: LRMR) has executed a securities purchase agreement to raise gross proceeds of approximately $95 million in a private placement. The proceeds will be used to support the...

3 months ago - Benzinga

Larimar Therapeutics Announces $95 Million Private Placement Financing

BALA CYNWYD, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

3 months ago - GlobeNewsWire

Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedr...

BALA CYNWYD, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

3 months ago - GlobeNewsWire

Why Is Larimar Therapeutics Stock Plunging Despite Positive CTI-1601 Data?

Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading lower despite announcing positive topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich...

4 months ago - Benzinga

Larimar Therapeutics Reports Positive CTI-1601 Data From Friedreich's Ataxia Trial

Larimar Therapeutics Inc (NASDAQ: LRMR) has announced topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich's Ataxia (FA). FA is a genetic, progre...

4 months ago - Benzinga

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxi...

BALA CYNWYD, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

4 months ago - GlobeNewsWire

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

- Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET

4 months ago - GlobeNewsWire

Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused i...

1 year ago - GlobeNewsWire

Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug

Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics into the commercializa...

2 years ago - Benzinga

Zafgen to Explore Strategic Alternatives

Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 Preliminary results from in vivo animal study not expected to warrant near-term r...

2 years ago - GlobeNewsWire

Micro-Cap Biotech Zafgen Plunges To Record Low: What You Need To Know

Shares of Zafgen Inc (NASDAQ: ZFGN) were tumbling below the psychological barrier of $2 in Thursday's session.

2 years ago - Benzinga

The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Zafgem said it has planned to suspend to file an investigational new drug application, or IND, for its ZGN-1258, which it's evaluating for rare metabolic disorders including Prader-Willi syndrome.

2 years ago - Benzinga